AZ, Merck, Sanofi The Winners In Drastic China Slowdown
This article was originally published in PharmAsia News
Executive Summary
A drastic slowdown in China has impacted pharma multinationals, with average growth dipping by double digits in the last quarter. PharmAsia News has combed through earnings reports to bring you the winners, laggards and the most successful strategies.